COMPARATIVE STUDY OF EFFECTIVENESS & SAFETY OF ATORVASTATIN PLUS FENOFIBRATE VERSUS ATORVASTATIN PLUS SAROGLITAZAR IN PATIENTS OF TYPE 2 DIABETES MELLITUS WITH DYSLIPIDEMIA

Dr. Sampada Rajurkar, *Dr. Deepak Bhosle and Dr. Dhiraj Chabda

ABSTRACT

Diabetes mellitus (DM) is an escalating global epidemic, representing a substantial menace to public health.[1] An estimated 537 million adults aged 20 to 79 worldwide are impacted by diabetes, representing approximately 10.5% of individuals in this age group. Several studies suggest that by 2030, the global diabetic population will reach approximately 643 million, with further growth to 783 million anticipated by 2045. In India, the burden of diabetes is substantial, with an estimated 77 million adults diagnosed in 2019, expected to rise to over 134 million by 2045. Alarmingly, around 57% of India's diabetic population remains undiagnosed, totalling about 43.9 million individuals accounting for a high economic burden advancing to approximately 1 million diabetes-related deaths reported.[3]

Keywords: .